A. Reynaud-Bougnoux

1.1k total citations
31 papers, 703 citations indexed

About

A. Reynaud-Bougnoux is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Reynaud-Bougnoux has authored 31 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Reynaud-Bougnoux's work include Breast Cancer Treatment Studies (13 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Radiotherapy Techniques (6 papers). A. Reynaud-Bougnoux is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Radiotherapy Techniques (6 papers). A. Reynaud-Bougnoux collaborates with scholars based in France. A. Reynaud-Bougnoux's co-authors include G. Calais, O. Le Floch, I. Barillot, S. Chapet, Philippe Bougnoux, Christine Berger, N. Huten, G. Body, Étienne Dorval and J. Lansac and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

A. Reynaud-Bougnoux

28 papers receiving 686 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Reynaud-Bougnoux France 11 333 289 249 208 119 31 703
Su Jung Shim South Korea 14 294 0.9× 303 1.0× 156 0.6× 145 0.7× 247 2.1× 34 819
C. Parsons United Kingdom 14 377 1.1× 349 1.2× 223 0.9× 160 0.8× 102 0.9× 42 912
Y. Otmezguine France 17 411 1.2× 244 0.8× 182 0.7× 507 2.4× 277 2.3× 42 821
Sait Okkan Türkiye 15 189 0.6× 183 0.6× 173 0.7× 152 0.7× 77 0.6× 39 654
Anand P. Shah United States 12 222 0.7× 103 0.4× 163 0.7× 137 0.7× 64 0.5× 25 488
Todd A. Pezzi United States 15 280 0.8× 114 0.4× 271 1.1× 72 0.3× 52 0.4× 37 566
Heidi Stranzl Austria 14 513 1.5× 264 0.9× 223 0.9× 536 2.6× 240 2.0× 29 1.1k
Benedetta Agresti Italy 12 137 0.4× 130 0.4× 166 0.7× 185 0.9× 65 0.5× 36 467
Karine Peignaux France 13 235 0.7× 292 1.0× 264 1.1× 69 0.3× 38 0.3× 46 617
Ji Hyeon Joo South Korea 13 125 0.4× 142 0.5× 151 0.6× 117 0.6× 65 0.5× 53 463

Countries citing papers authored by A. Reynaud-Bougnoux

Since Specialization
Citations

This map shows the geographic impact of A. Reynaud-Bougnoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Reynaud-Bougnoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Reynaud-Bougnoux more than expected).

Fields of papers citing papers by A. Reynaud-Bougnoux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Reynaud-Bougnoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Reynaud-Bougnoux. The network helps show where A. Reynaud-Bougnoux may publish in the future.

Co-authorship network of co-authors of A. Reynaud-Bougnoux

This figure shows the co-authorship network connecting the top 25 collaborators of A. Reynaud-Bougnoux. A scholar is included among the top collaborators of A. Reynaud-Bougnoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Reynaud-Bougnoux. A. Reynaud-Bougnoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tanguy, Marie‐Laure, Paul Cottu, Brigitte De La Lande, et al.. (2019). Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation. PLoS ONE. 14(8). e0221816–e0221816. 6 indexed citations
2.
Reynaud-Bougnoux, A., et al.. (2019). Grossesse après cancer du sein : revue de la littérature. La Presse Médicale. 48(4). 376–383. 4 indexed citations
3.
Belin, Lisa, Paul Cottu, P. Bontemps, et al.. (2018). Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer/Radiothérapie. 22(3). 222–228. 2 indexed citations
4.
Reynaud-Bougnoux, A., et al.. (2016). Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report. Cancer/Radiothérapie. 20(4). 275–281. 44 indexed citations
5.
Belin, Lisa, P. Cottu, P. Bontemps, et al.. (2015). Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. British Journal of Radiology. 88(1048). 20140800–20140800. 9 indexed citations
6.
7.
Dubray, Bernard, V. Beckendorf, S. Guérif, et al.. (2011). Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).. Journal of Clinical Oncology. 29(15_suppl). 4521–4521. 29 indexed citations
8.
9.
10.
11.
Berger, Christine, A. De Muret, P. Garaud, et al.. (1997). Preoperative radiotherapy (RT) for rectal cancer: Predictive factors of tumor downstaging and residual tumor cell density (RTCD): Prognostic implications. International Journal of Radiation Oncology*Biology*Physics. 37(3). 619–627. 156 indexed citations
12.
Calais, G., Étienne Dorval, Pascal Bourlier, et al.. (1997). Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for stages IIB and III esophageal carcinoma: Results of a pilot study. International Journal of Radiation Oncology*Biology*Physics. 38(4). 769–775. 45 indexed citations
13.
Berger, Christine, et al.. (1996). Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C. European Journal of Cancer. 32(10). 1707–1711. 5 indexed citations
14.
Calais, G., Christine Berger, Philippe Descamps, et al.. (1994). Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer. 74(4). 1283–1288. 106 indexed citations
15.
Chauvet, B., G. Body, C. Le Péchoux, et al.. (1992). Disappearance of the in situ component: a criterion predictive of metastasis in breast cancer after local relapse. Radiotherapy and Oncology. 25(3). 181–185. 3 indexed citations
16.
Calais, G., Philippe Descamps, A. Reynaud-Bougnoux, et al.. (1990). Lymphadenectomy in the management of endometrial carcinoma stage I and II. Retrospective study of 155 cases. Clinical Oncology. 2(6). 318–323. 8 indexed citations
17.
Chauvet, B., et al.. (1990). Prognostic significance of breast relapse after conservative treatment in node-negative early breast cancer. International Journal of Radiation Oncology*Biology*Physics. 19(5). 1125–1130. 51 indexed citations
18.
Descamps, Philippe, G. Body, A. Reynaud-Bougnoux, et al.. (1990). Preoperative or postoperative brachytherapy for patients with endometrial carcinoma stage I and II. International Journal of Radiation Oncology*Biology*Physics. 19(3). 523–527. 25 indexed citations
19.
Calais, G., et al.. (1990). Oropharynx carcinoma: irradiation alone versus induction chemotherapy plus irradiation—5 year results. British Journal of Radiology. 63(749). 340–345. 5 indexed citations
20.
Chauvet, B., C. Le Péchoux, J.-M. Simon, et al.. (1990). [Predisposing factors for local recurrence after conservative treatment of breast cancer].. PubMed. 33(6). 306–12. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Su Jung Shim Breakdown of academic impact, for papers by C. Parsons Breakdown of academic impact, for papers by Y. Otmezguine Breakdown of academic impact, for papers by Sait Okkan Breakdown of academic impact, for papers by Anand P. Shah Breakdown of academic impact, for papers by Todd A. Pezzi Breakdown of academic impact, for papers by Heidi Stranzl Breakdown of academic impact, for papers by Benedetta Agresti Breakdown of academic impact, for papers by Karine Peignaux Breakdown of academic impact, for papers by Ji Hyeon Joo
Rankless by CCL
2026